Pulmonary metastases neutralization and tumor rejection by in vivo administration of β glucan and bispecific antibody

International Journal of Cancer

Volumn 65, Issue 3, 1996, Pages 377-382

  Penna, Christophe ^a   Dean, Phillip A ^a   Nelson, Heidi ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; BISPECIFIC ANTIBODY; CD3 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; LYMPHOCYTE ACTIVATION; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, NEOPLASM; FEMALE; GLUCANS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; T-LYMPHOCYTES;

EID: 0030044851     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960126)65:3<377::AID-IJC17>3.0.CO;2-7     Document Type: Article

References (22)

1. DI RENZO, L., YEFENOF, E. and KLEIN, E., The function of human NK cells is enhanced by β-glucan, a ligand of CR3 (CD11b/CD18). Europ. J. Immunol., 21, 1755-1758 (1991).
2. ELLENHORN, J.D.I., HIRSCH, R., SCHREIBER, H. and BLUESTONE, J.A., In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science, 242, 569-571 (1988).
3. ESTIN, C.D., STEVENSON, U., KAHN, M., HELLSTROM, I. and HELLSTRÖM, K.E., Transfected mouse melanoma lines that express various levels of human melanoma-associated antigen p97. J. nat. Cancer Inst., 81, 445-448 (1989).
4. FIDLER, I.J., FOGLER, W.E., BROUWNBILL, A.F. and SCHUMANN, G., Systemic activation of tumoricidal properties of mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide. J. Immunol., 138, 4509-4514 (1987).
5. KARPOVSKY, B., TITUS, J.A., STEPHANY, D.A. and SEGAL, D.M., Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fcγ receptor antibodies. J. exp. Med., 160, 1686-1701 (1984).
6. LOTZE, M.T., MATORY, Y.L. ETTINGHALSEN, S.E., RAYNER, A.A., SHARROW, S.O., SEIPP, C.A.Y., CUSTER, M.C. and ROSENBERG. S.A., In vivo administration of purified human interleukin-2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J. Immunol., 135, 2865-2875 (1985).
7. NANBA, H. and KURODA, H., Potentiation of host-mediated antitumor activity by a β-glucan derived from mycelia of Cochliobolus miyabeanus. Chem. Pharm. Bull., 35, 1523-1530 (1987).
8. NELSON, H., MCKEAN, D.J., KERR, L.A. and DONOHUE, J.H., Antitumor × anti-CD3 heteroconjugates direct human peripheral blood lymphocytes to lyse colon tumor cells. J. surg. Res., 48, 284-290 (1990a).
9. NELSON, H., RAMSEY, P.S., KERR, L.A., MCKEAN, D.J. and DOSOHUE, J.H., Regional and systemic distribution of anti-tumor × anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft. J. Immunol., 145, 3507-3515 (1990b).
10. NELSON. H., RAMSEY. P.S., MCKEAN, D.J., DOZOIS, R. R. and DONOHUE, J.H., Anti-tumor × anti-lymphocyte heteroconjugates augment colon tumor cell lysts in vitro and prevent tumor growth in vivo. Dis. Colon Rectum. 34, 140-147 (1991).
11. NEWELL, K.A., ELLENHORN, J.D.I., BRUCE. D.S. and BLUESTONE, J.A., In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor. Proc. nat. Acad. Sci. (Wash.), 88, 1074-1078 (1991).
12. 2b from BALB/c mice. J. Immunol., 131, 2895-2902 (1983).
13. PENNA, C., DEAN, P.A. and NELSON, H., Antitumor × anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases. Cancer Res.. 54, 2738-2743 (1994).
14. PEREZ, P., TITUS, J.A., LOTZE, M.T., CUTTITTA, F., LONGO, D.L., GROVES, E.S., RABIN, H., DURDA, P.J. and SEGAL, D.M., Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody. J. Immunol., 137, 2069-2072 (1986).
15. RASMUSSEN, L.T. and SELJELID, R., Novel immunomodulators with pronounced in vivo effects caused by stimulation of cvtokine release. J. cell. Biochem., 46, 60-68 (1991).
16. REID, I., LUNDY, J. and DONOHUE, J.H., Enhancement of in vitro tumor-infiltrating lymphocyte cytotoxicity by heteroconjugated antibodies. J. Immunol. 148, 2630-2635 (1992a).
17. REID, I., LUNDY, J., MONSON, J., NELSON, H., RAMSEY, P., ILSTRUP. D. and DONOHUE, J., Heteroconjugated antibodies enhance lymphocytemediated tumour cell lysis in vitro and in vivo. Brit. J. Surg., 79, 628-632 (1992b).
18. ROSENBERG, S.A. and 15 OTHERS, Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with meta-static melanoma. New Engl. J. Med., 319, 1676-1680 (1988).
19. TOPALIAN, S.L., MUUL, L.M., SOLOMON, D. and ROSENBERG, S.A., Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Mesh., 102, 127-141 (1987).
20. WEINER, G.J., Bispecific IgG and IL-2 therapy of a syngeneic B-cell lymphoma in immunocompetent mice. Int. J. Cancer (Suppl. 7). 63-66 (1992).
21. WEST, W.H., TAUER, K.W., YANNELLI. J.R., MARSHALL, G.D., ORR. D.W., THURMAN, G.B. and OLDHAM, R.K., Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. New Engl. J. Med., 316, 898-905 (1987).
22. WEXLER, H., Accurate identification of experimental pulmonary metastases. J. nat. Cancer Inst., 36, 641-645 (1966).